|
|
Reliable Biopharmaceutical Corporation
A message from our President:
Since the founding of our company in 1968, Reliable Biopharmaceutical Corporation has based its success on the simple philosophy of responding to customer’s needs. We have used customer focused manufacturing, fueled by technical innovation, to create value for our customers, our employees and the local community.
After thirty-nine years of successful entrepreneurial leadership, the ownership of Reliable Biopharmaceutical Corporation (RBC) passed from the founding Ash family to Med Opportunity Partners in October 2007. Med Opportunity Partners, a private equity firm with an experienced management team and proven track record specializing in the healthcare industry, has brought new resources to RBC to enable faster growth and market penetration. Our new Board of Directors and advisors includes global experts in the pharmaceutical, bio-pharmaceutical and generic drug industries.
Over the last four decades, RBC has developed sophisticated API R&D and manufacturing capabilities, strong customer relationships with generic, branded pharmaceutical and biotechnology companies, and maintained positive relations with the FDA. RBC’s API customers include four of the six global leaders in generic injectable drugs as well as leading bio-pharmaceutical companies. We received a Supplier of the Year award from Eli Lilly in 2007.
2008 was our fifth consecutive year of sales and earnings growth as our business model continues to pay dividends. We now have thirteen active drug master files for the manufacture of active ingredients used in generic injectable pharmaceuticals as well as equivalent registrations for these products in countries outside of the United States.
Investment in resources and infrastructure continues. We added to our larger scale high potency manufacturing capabilities with a second containment suite for the manufacture of potent compounds commissioned in 2009, supported by the R&D and analytical facilities necessary to conduct and grow these businesses. Our capacity for high purity pharmaceutical processing chemicals also continues to grow as biologicals expand their therapeutic share in world-wide healthcare.
Our holistic approach to EHS management coordinated with FDA compliance has resulted in a safe, productive work place for our employees, the environment and the community. RBC maintains a high standard of safety and control within all manufacturing, analytical and packaging processes.
RBC is well positioned to develop and manufacture APIs for increasingly complex drug molecules that will lose patent protection over the next 10 years, including biological drugs. RBC’s potential pipeline of complex APIs projects includes 38 development projects for drugs that currently have approximately $5 billion of revenues. RBC’s addressable market opportunity in complex generic APIs will approximate $2-3 billion in 2010.
Michael E. Zaleski
President
Reliable Biopharmaceutical Corporation
|
 |
